Clinical Trial Update: Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates daratumumab for very high-risk T-cell acute lymphoblastic leukemia under the ALL National Treatment Program. The trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: T-Lymphocytic Leukemia, Acute | Phase 2 | Status: ACTIVE_NOT_RECRUITING